title: TNFerade, an innovative cancer immunotherapeutic.
abstract: Tumor necrosis factor-α (TNF-α) is a chemokine with effective tumoricidal properties. However, severe systemic toxicity limits its use of as anticancer agent. TNFerade is a novel replication deficient adenovector based gene therapy, which enables the radiation inducible translation of human TNF-α gene specifically in cancer cells. When injected intratumorally, it has least systemic distribution. Consequently, it lacks TNF-α related systemic toxicity. Evidence suggests that it has superior tumoricidal activity and tolerability with minimum adverse effects. It has demonstrated its beneficial role in the treatment of a variety of cancers in terms of improving the disease free and overall survival, delaying tumor progression, and inducing tumor regression when used with concurrent radiotherapy or chemotherapy.
authors.affiliation: Department of Microbiology, Mahatma Gandhi Medical College and Research Institute, Puducherry, India.
authors.forename: Arunava
authors.initials: A
authors.lastname: Kali
mesh_terms: D000818:Animals; D004247:DNA / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics*
chemical_list: C572333:TNFeraseBiologic; D014409:Tumor Necrosis Factor-alpha; D004247:DNA
keywords: Cancer immunotherapy; TNFerade; gene therapy; tumor necrosis factor-α